Results 21 to 30 of about 26,546,604 (291)

An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations

Frontiers in Public Health, 2021
Economic evidence is increasingly being used for informing health policies. However, the underlining principles of health economic analyses are not always fully understood by non-health economists, and inappropriate types of analyses, as well as ...
Hugo C. Turner, Rachel A. Archer, Laura E. Downey, Wanrudee Isaranuwatchai, Wanrudee Isaranuwatchai, Kalipso Chalkidou, Mark Jit, Mark Jit, Yot Teerawattananon, Yot Teerawattananon   +9 more
doaj   +1 more source

Cost-utility analysis of thrombolytic therapy [PDF]

European Heart Journal, 1991
An analysis of the cost-effectiveness of thrombolytic therapy was performed, based on 3- to 5-year follow-up data, from 533 patients randomized to receive conventional therapy or intracoronary streptokinase. At the 3-year follow-up, mortality was 22% in the former group and 14% after thrombolysis.
M L, Simoons, J, Vos, L L, Martens
openaire   +2 more sources

Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.

, 2019
Cost-utility analysis: Incremental cost-effectiveness ratio (ICER)—base case.
Frauke Becker (2836922), Denise Howel (16468), Catherine Haighton (2157001), Martin White (16466), Andrew Bryant (5704967), Terry Aspray (6194804), Luke Vale (3435356), Elaine McColl (533649), Suzanne Moffatt (16467), Sarah Lawson (6194801), Melanie Steer (6194798), Eugene M. G. Milne (2215138)   +11 more
core   +1 more source

Economic evaluation of using pesticides to control cutaneous leishmaniasis in Isfahan

Journal of Research in Pharmacy Practice, 2018
Objective: Pesticides have been used as the main part of the national cutaneous leishmaniasis control program for serveral years in Iran. However, the cost-effectiveness of this strategy has not been yet analyzed.
Ehsanallah Jafari, Maryam Moeeni, Reza Fadaei, Reza Rezayatmand   +3 more
doaj   +1 more source

Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis

Health Technology Assessment, 2023
Background Severe acute respiratory syndrome coronavirus 2 is the virus that causes coronavirus disease 2019. Over six million deaths worldwide have been associated with coronavirus disease 2019.
Metry Andrew, Pandor Abdullah, Ren Shijie, Shippam Andrea, Clowes Mark, Dark Paul, McMullan Ronan, Stevenson Matt   +7 more
doaj   +1 more source

Decision Rules in Cost-Utility Analysis of Health Technologies

Walailak Journal of Science and Technology, 2021
This review identified 4 distinct decision rules used in the cost-utility analysis of health technologies: threshold incremental cost-effectiveness ratio (ICER), league table, decision making (DM) plane, and linear programming.
Udomsak SAENGOW
doaj   +3 more sources

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Rebecca J. Deyell, Lesleigh Abbott, Tony H. Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +21 more
wiley   +1 more source

How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis [PDF]

PharmacoEconomics, 2017
Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire ...
Bojke, Laura, Manca, Andrea, Palmer, Stephen John, Asaria, Miqdad, Mahon, Ronan, Shijie (Kate), Ren   +5 more
openaire   +5 more sources

Neurocognitive, School‐Based, and Quality of Life Outcomes for Youth With Sickle Cell Disease and Thalassemia: A Scoping Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT The medical burdens of sickle cell disease (SCD) and transfusion‐dependent β‐thalassemia (TDT) are chronic and cumulative, even in children. Yet the effects expand beyond medications and healthcare visits due to their impacts on school attendance, academic performance, and peer engagement.
Mary Ann Etling, Hakim Tokhi, Alexander A. Boucher   +2 more
wiley   +1 more source

Association Between Individualized Education for Kidney Replacement Therapy Modality Selection and Peritoneal Dialysis Initiation: A Cross‐Sectional Study

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Peritoneal dialysis (PD) is an established home‐based kidney replacement therapy (KRT), but its uptake remains low in Japan. We evaluated whether individualized education in a dedicated outpatient clinic was associated with the initiation of PD.
Yasuko Ito, Ryuichi Yoshimura, Takaki Yamauchi, Yuta Funakoshi, Hirotaka Sonoda, Seiji Kobayashi, Hiroyuki Terawaki, Takafumi Ito   +7 more
wiley   +1 more source